Carbon 14 and Carbon 13 Syntheses of Velagliflozin
Bachir Latli1, Matt J Hrapchak1, Maxim Chevliakov1
1The Radiosynthesis Laboratory, Chemical Development, Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, Connecticut, USA.
Abstract:
Velagliflozin is the active ingredient of the first oral liquid medication approved by the Food and Drug Administration for the treatment of diabetes in cats. This compound belongs to the known class of sodium-glucose cotransporter 2 inhibitors approved to treat diabetes in human. Here, we report the detailed synthesis of velagliflozin labeled with carbon 14 and carbon 13.
More Related Videos
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Insulin: Biosynthesis, Chemistry, and Preparation
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Dipeptidyl Peptidase 4 Inhibitors
¹³C NMR: ¹H–¹³C Decoupling
A broadband decoupling technique is used to simplify these complex, sometimes overlapping, signals. Broadband decoupling relies on a...
Oral Hypoglycemic Agents: Sulfonylureas


